National Cancer Institute (NCI): Inflammatory Breast Neoplasms trials

The registry lists 11 Inflammatory Breast Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 4Phase 3 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast CancerActive, not recruitingNCT03598257Phase 2
• Case-Control Study of Inflammatory Breast Cancer in North AfricaCompletedNCT00793390
• Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With AngiogenesisCompletedNCT00646555
• Pilot Study of Inflammatory Breast Cancer in Egypt and TunisiaCompletedNCT00344071
• Establishing an Inflammatory Breast Cancer RegistryCompletedNCT00340158
• Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast CancerCompletedNCT00070252Phase 1/2
• Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast CancerCompletedNCT00049114Phase 2
• Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast CancerCompletedNCT00016549Phase 2
• Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast CancerTerminatedNCT00016276Phase 3
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast CancerCompletedNCT00001507Phase 1